Table 3. Significantly enriched gene pathways from Ingenuity Pathway Analysis.
| Top pathways | p-value | # of changed genes | |
| Diseases and disorders | Neurological diseases | 1.29E-05 | 591 |
| Cancer | 3.76E-05 | 455 | |
| Developmental disorder | 4.21E-05 | 500 | |
| Cardiovascular disease | 5.59E-05 | 440 | |
| Nutritional disease | 9.32E-05 | 182 | |
| Physiological development | Organismal development | 3.53E-06 | 993 |
| Organismal survival | 4.73E-06 | 621 | |
| Embryonic development | 3.47E-05 | 632 | |
| Organ development | 3.47E-05 | 557 | |
| Skeletal and muscular system development and function | 3.47E-05 | 393 | |
| Top toxicity lists | Cardiac hypertrophy | 6.41E-05 | 114/323 |
| Renal necrosis/cell death | 3.56E-04 | 128/383 | |
| Cardiac fibrosis | 4.71E-03 | 58/166 | |
| Mechanism of gene regulation by peroxisome proliferators via PPARa | 1.02E-02 | 35/95 | |
| Liver proliferation | 2.38E-02 | 61/189 | |
| Cardiotoxicity | Cardiac hypertrophy | 5.59E-05 | 115 |
| Pulmonary hypertension | 6.60E-04 | 22 | |
| Cardiac fibrosis | 2.43E-03 | 58 | |
| Cardiac arrhythmia | 1.44E-02 | 53 | |
| Cardiac output | 1.97E-02 | 15 |